M. Beauduin

2.7k total citations
70 papers, 1.2k citations indexed

About

M. Beauduin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Beauduin has authored 70 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in M. Beauduin's work include Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (16 papers) and Estrogen and related hormone effects (8 papers). M. Beauduin is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (16 papers) and Estrogen and related hormone effects (8 papers). M. Beauduin collaborates with scholars based in Belgium, France and United States. M. Beauduin's co-authors include F. Majois, Yves Humblet, J Longueville, P. Weynants, A. Vindevoghel, André Wambersie, Martine Piccart, Michel Symann, André Bosly and Charles K. Francis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Heart Journal.

In The Last Decade

M. Beauduin

67 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Beauduin Belgium 18 662 330 224 211 160 70 1.2k
Michael Fuchs Germany 29 1.2k 1.9× 672 2.0× 99 0.4× 136 0.6× 303 1.9× 161 2.7k
Torgil R. Möller Sweden 17 460 0.7× 349 1.1× 110 0.5× 111 0.5× 171 1.1× 29 1.3k
Akmal Safwat Denmark 22 676 1.0× 925 2.8× 163 0.7× 222 1.1× 282 1.8× 82 1.6k
Christel Fontaine Belgium 18 687 1.0× 356 1.1× 174 0.8× 408 1.9× 494 3.1× 73 1.5k
Thomas Kearney United States 19 739 1.1× 282 0.9× 921 4.1× 342 1.6× 186 1.2× 39 1.9k
Daniel Shasha United States 16 787 1.2× 646 2.0× 165 0.7× 125 0.6× 274 1.7× 55 1.7k
E Nordman Finland 16 482 0.7× 565 1.7× 134 0.6× 108 0.5× 152 0.9× 75 1.3k
B. Farrús Spain 21 579 0.9× 155 0.5× 382 1.7× 257 1.2× 402 2.5× 46 1.2k
Maureen Ross United States 20 1.0k 1.6× 288 0.9× 426 1.9× 176 0.8× 85 0.5× 61 1.8k

Countries citing papers authored by M. Beauduin

Since Specialization
Citations

This map shows the geographic impact of M. Beauduin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Beauduin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Beauduin more than expected).

Fields of papers citing papers by M. Beauduin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Beauduin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Beauduin. The network helps show where M. Beauduin may publish in the future.

Co-authorship network of co-authors of M. Beauduin

This figure shows the co-authorship network connecting the top 25 collaborators of M. Beauduin. A scholar is included among the top collaborators of M. Beauduin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Beauduin. M. Beauduin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Coudert, Bruno, Mario Campone, M. Spielmann, et al.. (2009). Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.. Cancer Research. 69(24_Supplement). 603–603. 8 indexed citations
2.
Rosier, Jean-François, et al.. (2004). Role of 2′-2′ difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas. Radiotherapy and Oncology. 70(1). 55–61. 9 indexed citations
3.
Focan, Christian, M. Beauduin, F. Majois, et al.. (2004). High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update. Clinical Breast Cancer. 5(2). 136–141. 8 indexed citations
4.
Focan, C., M. Beauduin, E. Salamon, et al.. (2001). Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. British Journal of Cancer. 85(1). 1–8. 27 indexed citations
5.
6.
Mitine, C., et al.. (1999). Radiotherapy of pelvic malignancies: impact of two types of rigid immobilisation devices on localisation errors. Radiotherapy and Oncology. 52(1). 19–27. 24 indexed citations
7.
8.
Focan, C., J Bury, M. Beauduin, et al.. (1995). Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report.. PubMed. 15(4). 1561–4. 1 indexed citations
9.
Hermans, J, et al.. (1995). [Contribution of TRH test and anti-TPO antibody assay in the screening of infraclinical hypothyroidism].. PubMed. 56(3). 219–24. 1 indexed citations
10.
Hermans, J, et al.. (1993). [Can benign and malignant thyroid nodules be differentiated with thallium 201?].. PubMed. 54(4). 248–54. 5 indexed citations
11.
Razavi, Darius, Nicole Delvaux, Christine Farvacques, et al.. (1993). Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam.. Journal of Clinical Oncology. 11(7). 1384–1390. 71 indexed citations
12.
D’Hondt, Véronique, P. Weynants, Yves Humblet, et al.. (1993). Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.. Journal of Clinical Oncology. 11(11). 2063–2071. 48 indexed citations
13.
Grégoire, V., M. Beauduin, Yves Humblet, et al.. (1991). A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.. Journal of Clinical Oncology. 9(8). 1385–1392. 15 indexed citations
14.
Minette, Philippe, et al.. (1991). Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma. European Journal of Cancer Prevention. 1(1). 57–68. 12 indexed citations
15.
Böhm, L., John Gueulette, D. T. L. Jones, et al.. (1990). Radiobiological intercomparison of two clinical neutron beams using the regeneration of mouse intestinal crypts.. PubMed. 166(3). 242–5. 5 indexed citations
16.
Humblet, Yves, P. Weynants, André Bosly, et al.. (1989). Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin. Medical Oncology and Tumor Pharmacotherapy. 6(3). 207–212. 14 indexed citations
17.
Majois, F., et al.. (1988). [A case of post-mastectomy lymphangiosarcoma].. PubMed. 88(6). 381–3. 2 indexed citations
18.
Gueulette, John, M. Beauduin, & André Wambersie. (1987). Mitotic Delay and its Variation With the Age of the Cells, After X-ray and Fast-neutron Irradiations - a Time-lapse Cinephotomicrographic Study. British Journal of Radiology. 60(711). 316–316. 2 indexed citations
19.
Beauduin, M., et al.. (1981). Le traitement conservateur du cancer du sein par la technique radiochirurgicale de Jolimont. Gyn�kologisch-geburtshilfliche Rundschau. 21(1). 177–186.
20.
Beauduin, M., et al.. (1978). [The interest of beta2-microglobulin in the cancer (author's transl)].. PubMed. 26(6). 343–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Fuchs Breakdown of academic impact, for papers by Torgil R. Möller Breakdown of academic impact, for papers by Akmal Safwat Breakdown of academic impact, for papers by Christel Fontaine Breakdown of academic impact, for papers by Thomas Kearney Breakdown of academic impact, for papers by Daniel Shasha Breakdown of academic impact, for papers by E Nordman Breakdown of academic impact, for papers by B. Farrús Breakdown of academic impact, for papers by Maureen Ross
Rankless by CCL
2026